ALKS
Alkermes Plc
NASDAQ · Healthcare · Biotechnology · IE
$45.49
−0.44%Year over year
Reported trailing growth
- Revenue
- +15.3%
- EBITDA
- -59.0%
- EBIT
- -82.1%
- EPS
- -99.9%
- Free cash flow
- -53.7%
- Operating cash flow
- -55.1%
Forward estimates
Based on analyst estimates
- Revenue
- +8.0%
- EBITDA
- -2.3%
- EPS
- —
Three-year CAGR
- Revenue
- +9.9%
- EBITDA
- +76.9%
- EBIT
- -21.7%
- Net income
- -17.6%
- EPS
- -17.1%
- Free cash flow
- +16.6%
Reported trailing growth, forward expectations and three-year compound growth rates · Data as of Sep 1, 2026